Warning: file_exists() [function.file-exists]: open_basedir restriction in effect. File(/home/nobody/cache/scraper/cache_getCompanyDetails_SCLL) is not within the allowed path(s): (/home/realp:/usr/lib/php:/usr/local/lib/php:/tmp) in /home/realp/public_html/components/com_stocksonline/library/class.cache.php on line 108

Warning: file_exists() [function.file-exists]: open_basedir restriction in effect. File(/home/nobody/cache/scraper/cache_getCompanyDetails_SCLL) is not within the allowed path(s): (/home/realp:/usr/lib/php:/usr/local/lib/php:/tmp) in /home/realp/public_html/components/com_stocksonline/library/class.cache.php on line 84
SCLL stock performance?

Pink Sheets: Stem Cell Innovations, Inc. (SCLL) financial news, and detailed stock charts

This company symbol is outdated. Results displayed are archieved for your information

Stem Cell Innovations, Inc. (SCLL/SCLL.PK) Penny Stock Summary:

Stem Cell Innovations, Inc., a cell biology company, engages in the development and production of its pluripotent stem cells in the United States. Its products include ACTIVTox, which measures various aspects of liver toxicity; and PREDICTIVTox, a database of information from compounds that allows chemists to organize and view the data to make structural decisions about the molecules. The company is also developing differentiated cell lines from its proprietary human pluripotent cells, adding to the cell types that may be used as a screen for drug discovery and toxicity, as well as for cellular replacement therapy. In addition, it develops its C3A human liver cell line for the production of human serum proteins, including the clotting factors used by hemophiliacs to allow their blood to clot; and develops other products, such as production of antibodies or the treatment of various diseases by in vivo cellular replacement therapy or in ex vivo applications, such as liver assist devices. Further, Stem Cell Innovations offers contract research and testing, and consulting services. Stem Cell Innovations, Inc. was formerly known as Interferon Sciences, Inc. The company was founded in 1980 and is based in Houston, Texas.

Pink Sheets: Archieved Financial News About Stem Cell Innovations, Inc.

Stem Cell Innovations to Provide Research and Assay Services to Agennix.

Quote: Kelly, PhD, CEO of Stem Cell Innovations. "Our C3A cells provide a reliable and reproducible foundation on which to base the talactoferrin assays."  In addition to the talactoferrin assays, SCLL will provide other research and cell culture services to Agennix. About AgennixAgennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients.  The Company's most a...
Read article

Stem Cell Innovations to Provide Research and Assay Services to Agennix.

Quote: Kelly, PhD, CEO of Stem Cell Innovations. "Our C3A cells provide a reliable and reproducible foundation on which to base the talactoferrin assays."  In addition to the talactoferrin assays, SCLL will provide other research and cell culture services to Agennix. About AgennixAgennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients.  The Company's most a...
Read article

STEM CELL INNOVATIONS, INC. Files SEC form 8-K, Other Events

Quote: Item 8.01 Other Events. Stem Cell Innovations, Inc., (SCLL.PK) wishes to update its shareholders on various aspects of the company over the past year. Our human embryonic germ cell technology has matured substantially. This work was significantly more difficult than originally anticipated but has resulted in a series of interesting and useful observations that will fill in several missing pieces in human stem cell biology. These observations are currently being finalized and assembled into a fo...
Read article

STEM CELL INNOVATIONS, INC. Files SEC form 8-K, Regulation FD Disclosure

Quote: 2009, Stem Cell Innovations, Inc. (the "Company"). entered into an agreement with Margie Chassman ("Chassman") and Alpha Capital Anstalt ("Alpha") pursuant to which Chassman agreed to provide $500,000 of financing to the Company over a six-month period commencing upon approval by the Company's stockholders of amendments to the Company's Certificate of Incorporation (the "Amendments") reducing the par value of the Company's common stock from $.01 per share ...
Read article

STEM CELL INNOVATIONS, INC. Files SEC form 8-K, Regulation FD Disclosure

Quote: 2008, Stem Cell Innovations, Inc. (the "Company") raised $300,000 through the issuance to Alpha Capital Anstalt ("Alpha"), an existing stockholder and noteholder of the Company, of a secured convertible note. The convertible note, due December 31, 2009, is in the principal amount of $300,000, bears interest at the rate of 15% per annum, is secured by all the assets of the Company and its subsidiaries, Amphioxus Cell Technologies, Inc. and ACTIVTox Laboratories, Inc. It is con...
Read article

You can still leave a comment about Stem Cell Innovations, Inc. SCLL/SCLL.PK

Besides Stem Cell Innovations, Inc.'s Penny Stock there is more great Microcap and Stock Market information available at Realpennies.com